Business Context and Reporting Period
This Form 8-K Current Report was filed by India Globalization Capital, Inc. (IGC Pharma, Inc.) on December 21, 2017, reporting events occurring on December 20, 2017. The filing discloses the entry into a material definitive agreement regarding a new equity financing mechanism.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization of an At-the-Market (ATM) Offering Agreement to sell up to $10,000,000 of the Company's common stock. The Company agreed to pay the sales agents a commission of 4.0% of the gross proceeds from any shares sold under this agreement.
Material Changes
The material change reported is the execution of an ATM Offering Agreement with The Benchmark Company LLC and Joseph Gunnar & Co., LLC. This agreement authorizes the sale of shares directly on the NYSE American or other trading markets. The agreement is set to automatically terminate on December 20, 2019, unless terminated earlier. This represents a new capability for the Company to raise capital opportunistically in the public market.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, earnings outlook, or management commentary regarding future financial performance. The document notes that the Company may suspend the offering upon notice. It also includes standard legal disclaimers stating that the report is not an offer to sell securities in jurisdictions where such an offer would be unlawful. The Company has agreed to indemnify the Managers against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the current share price and trading volume on the NYSE American to assess the potential dilution impact of the $10 million offering.
- Review the Company's existing shelf registration statement (Form S-3, File No. 333-201822) to confirm the total number of shares available for issuance.
- Examine the full text of the At-The-Market Offering Agreement (Exhibit 10.1) for specific conditions regarding suspension or termination.
- Check subsequent filings to determine if any shares have actually been sold under this agreement and the resulting gross proceeds.